News

 

 

Funding: New Awards

New Awards and Clinical Trials

Lionel Lewis, MD
Member, Molecular Therapeutics Research Program at Norris Cotton Cancer Center, and Professor of Medicine, Pharmacology & Toxicology

  • Amgen
    An open-label pharmacokinetic study of AMG 386 in advanced cancer subjects with normal and impaired renal function 

Kenneth Meehan, MD
Member, Immunology and Cancer Immunotherapy Research Program at Norris Cotton Cancer Center, and Professor of Medicine

  • Multiple Myeloma Research Foundation
    A prospective, longitudinal, observational study in newly diagnosed multiple myeloma (MM) patients to assess the relationship between patient outcomes, treatment regimens, and molecular profiles (Protocol MMRF-11-01)
  • Millennium Pharmaceuticals, Inc.
    An open-label, dose-escalation, Phase 1/2 study of the oral form of MLN9708, a next-generation proteasome inhibitor, administered in combination with a standard care regimen of melphalan and prednisone in patients with newly diagnosed multiple myeloma requiring systemic treatment (Sponsor Protocol #C16006)

Tracy Onega, PhD
Member, Cancer Control Research Program at Norris Cotton Cancer Center, and Assistant Professor, Community and Family Medicine

  • Norris Cotton Cancer Center
    Surveillance breast imaging in breast cancer survivors in the New Hampshire Mammography Network

James Rigas, MD
Member, Molecular Therapeutics Research Program at Norris Cotton Cancer Center, and Associate Professor of Medicine

  • Pfizer
    A randomized double blind Phase 3 efficacy and safety study of PF-00299804 versus erlotinib for the treatment of advanced non-small cell lung cancer following progression after, or intolerance to, at least one prior chemotherapy